<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758442</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2482</org_study_id>
    <nct_id>NCT04758442</nct_id>
  </id_info>
  <brief_title>Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology</brief_title>
  <acronym>Hemato-Vanco</acronym>
  <official_title>Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology: a Nomogram Based on a Bayesian Population Model to Predict Initial Dosage of Vancomycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center prospective pharmacokinetic study. The principal objective is to&#xD;
      collect new data among patients with hematologic cancer to develop a Bayesian population&#xD;
      pharmacokinetic model and to improve dose adjustment of intravenous vancomycin. Approximately&#xD;
      40 subjects meeting the inclusion and no exclusion criteria will be enrolled in the study.&#xD;
      Vancomycin blood concentration will be measured at steady-state at three different moment for&#xD;
      each participant : immediately before the infusion, 1 hour after the infusion and during the&#xD;
      elimination phase (at 3, 4 or 5 hours after the infusion). This additional vancomycin serum&#xD;
      concentration in the elimination phase will be used to estimate more precisely the vancomycin&#xD;
      pharmacokinetic parameters in this specific population including the distribution volume and&#xD;
      the elimination of the molecule. Ultimately, the purpose of this study is to create a&#xD;
      nomogram to predict the optimal initial vancomycin dosing in adult patients with a&#xD;
      hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
      Prospective, monocentric, pharmacokinetic study.&#xD;
&#xD;
      Adults who have been diagnosed with a hematologic malignancy, are hospitalized at&#xD;
      Maisonneuve-Rosemont hospital and received at least 3 doses of intravenous vancomycin.&#xD;
&#xD;
      Pharmacokinetic parameters: Serum vancomycin concentration measured at steady state just&#xD;
      before the beginning of the infusion (trough), 1 hour after completion of the infusion (peak)&#xD;
      and between 3 to 5 hours after the end of the infusion (additional blood draw during the&#xD;
      elimination phase).&#xD;
&#xD;
      RECRUITMENT PROCESS:&#xD;
&#xD;
      A systematic daily screening of hospitalized patients diagnosed with a hematologic cancer&#xD;
      will be made by the research team and the pharmacists 7 days a week. An information sheet&#xD;
      will be given to all potential eligible patients at their admission. When intravenous&#xD;
      vancomycin is prescribed, a member of the research team will explain the study and present&#xD;
      the Information and Consent Form (ICF) to the potential participant to obtain his/her&#xD;
      official informed consent.&#xD;
&#xD;
      DATA COLLECTION:&#xD;
&#xD;
      Three blood draws will be planned around the fourth or fifth dose of vancomycin and collected&#xD;
      by the nursing team. The sampling scheme is as follows: just before the beginning of the&#xD;
      infusion (trough), 1 hour after completion of the infusion (peak) and 3, 4 or 5 hours after&#xD;
      the end of the infusion (additional blood draw during the elimination phase) according to the&#xD;
      assigned time of the participant. The assigned time of the additional blood draw will be&#xD;
      randomized at the inclusion of the subject in the study. A member of the research team will&#xD;
      provide the tubes to the nurse, will write and save sampling times and will ship the blood&#xD;
      samples to the laboratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters : Volume of Distribution</measure>
    <time_frame>During intravenous vancomycin treatment assessed to 72 hours</time_frame>
    <description>Estimated from vancomycin serum concentrations and patient characteristics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters : Vancomycin clearance</measure>
    <time_frame>During intravenous vancomycin treatment assessed to 72 hours</time_frame>
    <description>Estimated from vancomycin serum concentrations and patient characteristics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the concentration-time Curve (AUC)</measure>
    <time_frame>between 0 to 24 hours during vancomycin administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vancomycin Through Concentration</measure>
    <time_frame>5 minutes before the selected infusion</time_frame>
    <description>Vancomycin concentration measured just before the next infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vancomycin Peak Concentration</measure>
    <time_frame>60 minutes after the end of the infusion</time_frame>
    <description>Vancomycin concentration measured 1 hour after the end of vancomycin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vancomycin Elimination Phase Concentration</measure>
    <time_frame>3 to 5 hours after the end of the infusion (+/- 30 minutes)</time_frame>
    <description>Vancomycin concentration measured 3 to 5 hours after the end of vancomycin infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vancomycin</condition>
  <condition>Hematologic Malignancies</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with hematologic cancer who received intravenous vancomycin for a suspected or confirmed infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional blood sample</intervention_name>
    <description>Included subjects will provided three blood samples to follow vancomycin concentration</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 18 and over;&#xD;
&#xD;
          -  Subjects diagnosed with a hematologic cancer;&#xD;
&#xD;
          -  Subjects hospitalized at Maisonneuve-Rosemont hospital between February 2021 and&#xD;
             August 2021;&#xD;
&#xD;
          -  Intravenous vancomycin treatment prescribed by a doctor;&#xD;
&#xD;
          -  Subjects received at least 3 doses of intravenous vancomycin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-malignant diagnosis (aplastic anemia and rare metabolic diseases);&#xD;
&#xD;
          -  Subjects admitted to a critical care unit;&#xD;
&#xD;
          -  End-stage renal disease (GFR &lt; 15 mL/min/1.73m2);&#xD;
&#xD;
          -  Patients undergoing dialysis/renal replacement therapy;&#xD;
&#xD;
          -  Acute kidney injury at the moment of the first vancomycin dosage (definition adapted&#xD;
             from KDIGO criteria):&#xD;
&#xD;
               1. Increase in serum creatinine by ≥ 26.5 umol/L within 48 hours or&#xD;
&#xD;
               2. Increase in serum creatinine to ≥ 1.5 times baseline within prior 7 days&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  Severely burn patients;&#xD;
&#xD;
          -  Inability to give free and informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annie Brisebois-Boyer, Pharm.D, M. Sc</last_name>
    <phone>514-252-3400</phone>
    <phone_ext>1553</phone_ext>
    <email>abriseboisboyer.hmr@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>TEAM HEMATO-VANCO, Pharm. D</last_name>
    <phone>514-252-3400</phone>
    <phone_ext>6124</phone_ext>
    <email>residents.phm2021.cemtl@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.</citation>
    <PMID>21258094</PMID>
  </reference>
  <reference>
    <citation>Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am. 2010 Jun;24(2):257-72. doi: 10.1016/j.idc.2010.01.010. Review.</citation>
    <PMID>20466269</PMID>
  </reference>
  <reference>
    <citation>Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434. Review. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887.</citation>
    <PMID>19106348</PMID>
  </reference>
  <reference>
    <citation>Pfizer Canada Inc. PRODUCT MONOGRAPH : VANCOMYCIN HYDROCHLORIDE FOR INJECTION, USP. Kirkland, QC Pfizer Canada Inc.;2018.</citation>
  </reference>
  <reference>
    <citation>Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. Review.</citation>
    <PMID>16323118</PMID>
  </reference>
  <reference>
    <citation>Zhao W, Zhang D, Fakhoury M, Fahd M, Duquesne F, Storme T, Baruchel A, Jacqz-Aigrain E. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease. Antimicrob Agents Chemother. 2014 Jun;58(6):3191-9. doi: 10.1128/AAC.02564-13. Epub 2014 Mar 24.</citation>
    <PMID>24663023</PMID>
  </reference>
  <reference>
    <citation>Okada A, Kariya M, Irie K, Okada Y, Hiramoto N, Hashimoto H, Kajioka R, Maruyama C, Kasai H, Hamori M, Nishimura A, Shibata N, Fukushima K, Sugioka N. Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Pharmacol. 2018 Sep;58(9):1140-1149. doi: 10.1002/jcph.1106. Epub 2018 May 15.</citation>
    <PMID>29762865</PMID>
  </reference>
  <reference>
    <citation>Aljutayli A, Marsot A, Nekka F. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults. Clin Pharmacokinet. 2020 Jun;59(6):671-698. doi: 10.1007/s40262-020-00866-2. Review.</citation>
    <PMID>32020531</PMID>
  </reference>
  <reference>
    <citation>Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012 Jan 1;51(1):1-13. doi: 10.2165/11596390-000000000-00000. Review.</citation>
    <PMID>22149255</PMID>
  </reference>
  <reference>
    <citation>Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58(1):309-16. doi: 10.1128/AAC.01653-13. Epub 2013 Oct 28.</citation>
    <PMID>24165176</PMID>
  </reference>
  <reference>
    <citation>Bury D, Ter Heine R, van de Garde EMW, Nijziel MR, Grouls RJ, Deenen MJ. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. Eur J Clin Pharmacol. 2019 Jul;75(7):921-928. doi: 10.1007/s00228-019-02657-6. Epub 2019 Mar 15.</citation>
    <PMID>30877327</PMID>
  </reference>
  <reference>
    <citation>Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012 Mar;18(1):91-6. doi: 10.1177/1078155211402107. Epub 2011 Apr 26.</citation>
    <PMID>21521799</PMID>
  </reference>
  <reference>
    <citation>Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, García MJ. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005 Dec;49(12):4934-41.</citation>
    <PMID>16304155</PMID>
  </reference>
  <reference>
    <citation>Choi MH, Choe YH, Lee SG, Jeong SH, Kim JH. Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin. Clin Chim Acta. 2017 Feb;465:106-111. doi: 10.1016/j.cca.2016.12.021. Epub 2016 Dec 23.</citation>
    <PMID>28025029</PMID>
  </reference>
  <reference>
    <citation>Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011 Dec;55(12):5475-9. doi: 10.1128/AAC.00168-11. Epub 2011 Sep 26.</citation>
    <PMID>21947388</PMID>
  </reference>
  <reference>
    <citation>Taghizadeh-Ghehi M, Rezaee S, Gholami K, Hadjibabaie M. Predictive performance of Vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation. J Res Pharm Pract. 2015 Jul-Sep;4(3):129-34. doi: 10.4103/2279-042X.162357.</citation>
    <PMID>26311080</PMID>
  </reference>
  <reference>
    <citation>Monteiro JF, Hahn SR, Gonçalves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018 Jul;6(4):e00420. doi: 10.1002/prp2.420.</citation>
    <PMID>30156005</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bayesian model</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

